NVision has developed a quantum-based platform which polarizes natural metabolites, enabling these safe molecules to be used as an agent for imaging tumor metabolism via standard MRI. This safe imaging technology will provide clinicians worldwide unprecedented early insights into treatment efficacy, allowing non-responders to be moved onto another line of therapy more quickly. The company is based in Ulm, Germany, and active throughout the US and Europe.
Investor: Private Investor Network, Industrial Tech Fund
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.